Company intelligence / Profile preview

Aland Health

Jingjiang, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Aland was a major manufacturer of vitamin C and other nutritional products. The company also held regulatory approval for the classic antibiotic small molecule sulfadiazine, with an approved indication in bacterial infections. The clinical stage of this asset is commercial, and its first approval occurred in 1941, though Aland's involvement is more recent.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Food & Nutrition

Beyond the preview

Go deeper on Aland Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aland Health.

Explore the full profile